LISATA THERAPEUTICS, INC. — Form 8-K
Filed September 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
Lisata Therapeutics (public market cap ~$23.6M) agreed to merge with private biotech Marea Therapeutics in a two-step merger dated September 17, 2026. Marea stockholders receive 1,793,129 shares of Lisata common stock (capped at 19.9% of Lisata's outstanding shares pre-closing) plus up to 211,365 shares of Lisata Series C Preferred Stock (each convertible into 1,000 common shares, subject to stockholder vote). The transaction also includes a concurrent PIPE investment. No dollar purchase price stated; consideration structured entirely in Lisata equity.
Why this rating
All-stock reverse merger with private company; transforms Lisata into combined entity. Issuance cap and preferred conversion require stockholder approval. Material event for ~$24M company; highly dilutive if conversion occurs.
Tradability signal
NO TRADE
No trade: positive news with only +0.0% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +2.25% over 4 hrs, n=10). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $1.47 | +10 min · unknown $1.47 ▲ 0.00% | +30 min · unknown $1.66 ▲ 13.13% | +1 hr · unknown $1.68 ▲ 14.29% | +4 hrs · unknown $1.77 ▲ 20.41% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.